Sugi Predict

Sugi Predict / Targets / BTD

BTD

Biotinidase · P43251 · BTD on Sugi Atlas →

690 patent compounds predicted against BTD, 391 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL19779557 SCHEMBL19779557 0.68 9/20
SCHEMBL19779437 SCHEMBL19779437 1.00 7/20
SCHEMBL24326918 SCHEMBL24326918 0.61 7/20
SCHEMBL24326913 SCHEMBL24326913 0.57 7/20
SCHEMBL24326930 SCHEMBL24326930 0.56 7/20
SCHEMBL24326924 SCHEMBL24326924 0.55 7/20
SCHEMBL19779418 SCHEMBL19779418 1.00 6/20
SCHEMBL19779518 SCHEMBL19779518 1.00 6/20
SCHEMBL19779548 SCHEMBL19779548 1.00 6/20
SCHEMBL21480162 SCHEMBL21480162 0.92 6/20
SCHEMBL21480222 SCHEMBL21480222 0.87 6/20
Pfi-653 Pfi-653 (SCHEMBL19779340) 0.86 6/20
Pfi-653-N Pfi-653-N (SCHEMBL19779420) 0.63 6/20
SCHEMBL21460198 SCHEMBL21460198 1.00 5/20
SCHEMBL21480187 SCHEMBL21480187 1.00 5/20
SCHEMBL21480153 SCHEMBL21480153 0.87 5/20
SCHEMBL21485012 SCHEMBL21485012 0.86 5/20
SCHEMBL21480277 SCHEMBL21480277 0.83 5/20
SCHEMBL21480192 SCHEMBL21480192 0.80 5/20
SCHEMBL21480229 SCHEMBL21480229 0.80 5/20

Clinical trials — most relevant to BTD by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Biotin on Routine Laboratory Values PHASE4COMPLETED
Copper Histidine Therapy for Menkes Diseases PHASE1/PHASE2COMPLETED
Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency PHASE2COMPLETED
A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease PHASE2COMPLETED
Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency PHASE2COMPLETED
A Study to Investigate the Mass Balance of BTD-001 PHASE1COMPLETED
Biotin-RBC Transfusion in SCD PHASE1COMPLETED
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment PHASE1COMPLETED
Neonatal Screening of Biotinidase Deficiency: Genotype-phenotype Correlation and Clinical Follow-up nanRECRUITING
EXOMIND (BTL-699) for the Reduction of Food Cravings nanCOMPLETED
The Acute Interference of Biotin in Blood Analysis nanRECRUITING
EXOMIND (BTL-699-2) for Improvement of Mental Well-being nanCOMPLETED
Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis nanRECRUITING
EEG Changes After rTMS Stimulation nanCOMPLETED
GBE Deficiency (GSD IV and APBD) Natural History Study nanRECRUITING
Local Sensory Nerve Block in the Treatment of Vestibular Migraine nanCOMPLETED
Gait Analysis in MPS IVA nanCOMPLETED
EXOMIND (BTL-699-2) for the Improvement in Willpower & Food Cravings nanCOMPLETED
Child & Adolescent Bipolar Disorder Brain Imaging and Treatment Study nanCOMPLETED
SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease nanUNKNOWN
Prevalence of High Plasmatic 3OMethyldopa Level in a Specific Population of Patients With a Symptomatology Compatible With AADC Deficiency nanUNKNOWN
Pattern of Metabolic Causes of Neonatal Hypoglycemia nanUNKNOWN
Impact of Specific Oligomeric Supplementation in Oncologic Patients Undergoing Radiotherapy With Malnutrition or at Risk. nanENROLLING_BY_INVITATION
Early Detection of Breast Cancer in Women With Suspicious Mammograms nanACTIVE_NOT_RECRUITING
Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease nanCOMPLETED
Genotype-Phenotype Correlations of Late Infantile Neuronal Ceroid Lipofuscinosis nanCOMPLETED
Retrospective Natural History Study of Infants and Toddlers With LAMA2-CMD nanCOMPLETED
Potential Synergistic Effect of Combined Blood Flow Restriction Training and Betaine Supplementation on Skeletal Muscle nanCOMPLETED
Newborn Genomic Sequencing Pilot Study nanCOMPLETED
Registry Gangliosidoses nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a BTD binder may also engage these)

ProteinNameSimilarity
Q5FVF9 — 0.997 Q5FVF9 →
A6QQ07 — 0.996 A6QQ07 →
Q8CIF4 — 0.995 Q8CIF4 →
P83548 — 0.990 P83548 →
O95498 — 0.989 O95498 →
Q8IRR1 — 0.985 Q8IRR1 →
Q9Z0K8 — 0.985 Q9Z0K8 →
Q9NFP1 — 0.983 Q9NFP1 →
Q9WTZ2 — 0.981 Q9WTZ2 →
A1X150 — 0.981 A1X150 →
P0DSP1 — 0.981 P0DSP1 →
Q8BG22 — 0.981 Q8BG22 →
Q00PJ8 — 0.980 Q00PJ8 →
Q9TSX8 — 0.980 Q9TSX8 →
Q8AV84 — 0.980 Q8AV84 →
Q9DBX3 — 0.980 Q9DBX3 →
Q9Z2A8 — 0.980 Q9Z2A8 →
Q9WTZ3 — 0.980 Q9WTZ3 →
Q95209 — 0.979 Q95209 →
Q765H6 — 0.979 Q765H6 →
Q9BDJ5 — 0.979 Q9BDJ5 →
O88917 — 0.979 O88917 →
Q6NQ51 — 0.979 Q6NQ51 →
Q5R7P4 — 0.978 Q5R7P4 →
Q769I5 — 0.978 Q769I5 →
Q07E01 — 0.978 Q07E01 →
Q75ZY9 — 0.978 Q75ZY9 →
Q60HF6 — 0.978 Q60HF6 →
P23613 — 0.978 P23613 →
Q2IBC0 — 0.978 Q2IBC0 →